However, concerns have been raised about the effectiveness of Covaxin as it received emergency regulatory approval prior to the completion of the Phase 3 clinical trials. The regulator and the manufacturer have stated that the vaccine is safe and that efficacy data will be available by February.

LEAVE A REPLY

Please enter your comment!
Please enter your name here